In the context of the ODDO BHF Forum, we had the opportunity to get an update on management's short- and medium-term ambitions. The next few months are set to be transformative for Medincell, with 1/ the ramp-up in sales of Uzedy, 2/ the launch of Olanzapine LAI, considered by its partner Teva to be a blockbuster, and 3/ the entry into clinical trials of its first drug candidate from its partnership with Abbvie. These commercial, regulatory and clinical milestones will likely support the share p...
Dans le cadre du Forum ODDO BHF, nous avons eu l’occasion de revenir sur les ambitions à court et moyen termes du management. Aussi, les prochains mois de Medincell devraient être transformants avec 1/ la montée en puissance des ventes d’Uzedy, 2/ le lancement d’Olanzapine LAI considéré par son partenaire Teva comme un blockbuster et 3/ l’entrée en clinique de son 1er candidat médicament venant de son partenariat avec Abbvie. Ces milestones commerciaux, réglementaires et cliniques devraient perm...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.